The deterministic health profile is critically weak, headlined by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the stock has seen a massive 1-year price surge of 137.2%, this is fundamentally unsupported by a negative profit margin (-7.05%) and a negative ROE (-16.93%). Despite a low Price/Sales ratio of 0.81 and a reasonable forward P/E, the combination of stagnant revenue growth (2%) and a bearish technical trend (10/100) suggests the recent rally was speculative rather than fundamental. The lack of an Altman Z-Score and Graham Number further complicates valuation, but the underlying health metrics are a significant red flag.